RxDoctor Payments Data

Heather Hunemuller

Nurse Practitioner · Davenport, IANPI 1649419219

Payments from drug & device makers

$1,763in general payments, 2019–2025

Across 79 payments — averaging $22.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$527
  • AstraZeneca$242
  • AbbVie$203
  • Pfizer$171
  • Corcept Therapeutics$126
  • Gilead$122
  • plus $373 from 8 others

What the payments were for

  • Food & beverage$1,763100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,763 in reported general payments places this provider in the 90th percentile of 1,346 nurse practitioner providers in Iowa.

See all nurse practitioner providers in Iowa

Medicare billing

Part B allowed, 2024
$56,710
Medicare patients
136
Services billed
546

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala325$1,269,201
OdefseyEmtricitab/Rilpiviri/Tenof Ala266$964,169
TriumeqAbacavir/Dolutegravir/Lamivudi149$561,949
GenvoyaElviteg/Cob/Emtri/Tenof Alafen118$498,288
DescovyEmtricitabine/Tenofov Alafenam124$279,204
IsentressRaltegravir Potassium99$197,096
TivicayDolutegravir Sodium73$166,266
PrezcobixDarunavir/Cobicistat47$114,324
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf18$110,989
Darunavir84$73,641
CabenuvaCabotegravir/Rilpivirine12$72,270
Etravirine60$57,844
Isentress HdRaltegravir Potassium23$40,706
JulucaDolutegravir/Rilpivirine11$37,789
PrezistaDarunavir18$35,116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$122$2,046,694567 claims
Viiv Healthcare CompanyTriumeq, Tivicay, Cabenuva, Juluca$527$838,274245 claims
MerckIsentress, Isentress Hd$37$237,802122 claims
Johnson & JohnsonPrezcobix, Xarelto$42$126,71370 claims
Boehringer IngelheimJardiance$112$31,60153 claims
AstraZenecaSymbicort, Bevespi Aerosphere$242$11,27943 claims
PfizerEliquis$171$8,71013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,346 nurse practitioner providers in Iowa.

Other nurse practitioner in Davenport

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →